Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Democratizing LYTACs-A Modular Click Chemistry Platform for the Rapid Assembly of Lysosome-Targeting Chimeras.

Created on 31 Aug 2026

Authors

Peter A Szijj, Sherry Li, Madeline K Gilbert, Chloë Wood Rollock, Mariko Morimoto, Carolyn R Bertozzi

Published in

ACS chemical biology. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

Lysosome-targeting chimeras (LYTACs) are emerging therapeutics that mediate extracellular targeted protein degradation. Through simultaneous engagement of a target protein of interest and a lysosomal trafficking receptor, these bifunctional molecules can facilitate the degradation of both secreted and cell-surface proteins. The original LYTACs were designed to engage the cation-independent mannose-6-phosphate receptor (CI-M6PR) via complex glycopolymer or glycopolypeptide ligands conjugated to target-specific antibodies. However, the complexity of these ligands has limited the broader adoption of LYTACs as research tools. Here, we describe a simple, rapid, and modular click chemistry platform for the generation of CI-M6PR-binding LYTACs. The approach utilizes only commercially available reagents and standard laboratory equipment and allows for the conversion of virtually any antibody into a LYTAC. This method for "democratizing" LYTAC generation should facilitate the widespread adoption of these tools for biological discovery.

PMID:
42669291
Bibliographic data and abstract were imported from PubMed on 31 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement